MedTrace Logo

Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

NCT06842199 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 383

Last updated 2026-02-09

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy, safety, PK characteristics of ICP-488 in Chinese adults with moderate to severe plaque psoriasis.

Conditions

  • Plaque Psoriasis Patients

Interventions

DRUG

ICP-488 Tablets

Eligible patients will receive ICP-488 orally as per the protocol

DRUG

ICP-488 Placebo

Eligible patients will receive ICP-488 Placebo orally as per the protocol

Sponsors & Collaborators

  • Beijing InnoCare Pharma Tech Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-20
Primary Completion
2026-05-31
Completion
2027-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06842199 on ClinicalTrials.gov